Marksans Pharma Gelecekteki Büyüme
Future kriter kontrolleri 3/6
Marksans Pharma kazanç ve gelirin sırasıyla yıllık 18.3% ve 13.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 18.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.8% olacağı tahmin edilmektedir.
Anahtar bilgiler
18.3%
Kazanç büyüme oranı
18.37%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 16.1% |
| Gelir büyüme oranı | 13.8% |
| Gelecekteki özkaynak getirisi | 15.80% |
| Analist kapsamı | Low |
| Son güncelleme | 28 May 2026 |
Gelecekteki son büyüme güncellemeleri
Analiz Makalesi • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...Analiz Makalesi • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Analiz Makalesi • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Analiz Makalesi • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Recent updates
Anlatı Güncellemesi • Jun 23
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.
Yeni Anlatı • Jun 15
Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Yeni Anlatı • Jun 01
Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceutical company focused on generic formulations across regulated markets including North America, the U.K., Europe, Australia and New Zealand. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...Analiz Makalesi • May 28
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analiz Makalesi • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Analiz Makalesi • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Analiz Makalesi • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Anlatı Güncellemesi • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Analiz Makalesi • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Anlatı Güncellemesi • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Analiz Makalesi • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Analiz Makalesi • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Analiz Makalesi • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...Analiz Makalesi • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...Analiz Makalesi • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Analiz Makalesi • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analiz Makalesi • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Analiz Makalesi • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Analiz Makalesi • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
Yeni Anlatı • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Analiz Makalesi • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Analiz Makalesi • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analiz Makalesi • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Analiz Makalesi • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Analiz Makalesi • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Analiz Makalesi • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analiz Makalesi • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Analiz Makalesi • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analiz Makalesi • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 3/31/2029 | 45,800 | 7,689 | N/A | 6,595 | 1 |
| 3/31/2028 | 39,311 | 6,113 | 4,228 | 5,403 | 3 |
| 3/31/2027 | 34,903 | 5,377 | 2,888 | 4,790 | 2 |
| 3/31/2026 | 29,509 | 4,179 | 3,276 | 4,581 | N/A |
| 12/31/2025 | 28,033 | 3,603 | N/A | N/A | N/A |
| 9/30/2025 | 27,307 | 3,517 | 346 | 2,047 | N/A |
| 6/30/2025 | 26,522 | 3,501 | N/A | N/A | N/A |
| 3/31/2025 | 26,228 | 3,806 | 337 | 2,067 | N/A |
| 12/31/2024 | 24,744 | 3,683 | N/A | N/A | N/A |
| 9/30/2024 | 23,787 | 3,470 | 520 | 2,169 | N/A |
| 6/30/2024 | 22,680 | 3,338 | N/A | N/A | N/A |
| 3/31/2024 | 21,774 | 3,137 | 216 | 2,304 | N/A |
| 12/31/2023 | 21,034 | 3,164 | N/A | N/A | N/A |
| 9/30/2023 | 19,971 | 2,965 | 894 | 2,528 | N/A |
| 6/30/2023 | 19,184 | 2,743 | N/A | N/A | N/A |
| 3/31/2023 | 18,521 | 2,663 | 1,838 | 2,374 | N/A |
| 12/31/2022 | 17,842 | 2,123 | N/A | N/A | N/A |
| 9/30/2022 | 16,670 | 2,004 | 972 | 1,286 | N/A |
| 6/30/2022 | 15,756 | 1,847 | N/A | N/A | N/A |
| 3/31/2022 | 14,908 | 1,868 | 529 | 993 | N/A |
| 12/31/2021 | 14,069 | 2,367 | N/A | N/A | N/A |
| 9/30/2021 | 14,026 | 2,473 | 883 | 1,336 | N/A |
| 6/30/2021 | 14,064 | 2,518 | N/A | N/A | N/A |
| 3/31/2021 | 13,762 | 2,385 | 1,322 | 1,786 | N/A |
| 12/31/2020 | 13,817 | 2,018 | N/A | N/A | N/A |
| 9/30/2020 | 13,142 | 1,724 | 1,839 | 2,478 | N/A |
| 6/30/2020 | 12,203 | 1,476 | N/A | N/A | N/A |
| 3/31/2020 | 11,344 | 1,208 | 1,734 | 2,333 | N/A |
| 12/31/2019 | 10,463 | 879 | N/A | N/A | N/A |
| 9/30/2019 | 9,972 | 834 | N/A | 416 | N/A |
| 6/30/2019 | 10,099 | 780 | N/A | N/A | N/A |
| 3/31/2019 | 10,001 | 804 | N/A | 274 | N/A |
| 12/31/2018 | 9,523 | 666 | N/A | N/A | N/A |
| 9/30/2018 | 9,223 | 582 | N/A | N/A | N/A |
| 6/30/2018 | 9,272 | 463 | N/A | N/A | N/A |
| 3/31/2018 | 9,127 | 358 | N/A | 501 | N/A |
| 12/31/2017 | 8,918 | 343 | N/A | N/A | N/A |
| 9/30/2017 | 8,949 | 275 | N/A | N/A | N/A |
| 6/30/2017 | 8,015 | 187 | N/A | N/A | N/A |
| 3/31/2017 | 7,672 | 113 | N/A | 141 | N/A |
| 12/31/2016 | 7,926 | 70 | N/A | N/A | N/A |
| 9/30/2016 | 7,948 | 136 | N/A | N/A | N/A |
| 6/30/2016 | 8,699 | 481 | N/A | N/A | N/A |
| 3/31/2016 | 8,933 | 785 | N/A | 308 | N/A |
| 12/31/2015 | 8,536 | 1,093 | N/A | N/A | N/A |
| 9/30/2015 | 8,495 | 1,191 | N/A | N/A | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: MARKSANS 'nin tahmini kazanç büyümesi (yıllık 18.3% ) tasarruf oranının ( 6.9% ) üzerindedir.
Kazançlar ve Piyasa: MARKSANS şirketinin kazançlarının (yıllık 18.3% ) Indian pazarından (yıllık 16.3% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: MARKSANS şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.
Gelir ve Pazar: MARKSANS şirketinin gelirinin (yıllık 13.8% ) Indian pazarından (yıllık 11% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: MARKSANS şirketinin gelirinin (yıllık 13.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: MARKSANS 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.8 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 13:43 |
| Gün Sonu Hisse Fiyatı | 2026/07/06 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Marksans Pharma Limited 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |